Tactile Systems Technology, Inc. (TCMD)

NGM – Real Time Price. Currency in USD

23.53

-0.37 (-1.55%)

At close: May 12, 2026, 4:00 PM EDT

06.05.2026

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

05.05.2026

Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript

04.05.2026

Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates

Tactile Systems Technology (TCMD) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.13 per share a year ago.

04.05.2026

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Summary and Recent Business Highlights: Total revenue increased 23% year-over-year to $75.3 million Gross margin of 76.5% versus 74% in Q1 2025 Net loss of $1.8 million versus $3.0 million in Q1 2025 Adjusted EBITDA of $3.7 million versus an Adjusted EBITDA loss of $0.3 million in Q1 2025 Expanded AI-enabled order management platform with the implementation of new operational capabilities to execute the Medicare prior authorization requirement for PCDs Repurchased $1.1 million of stock under the Company's share repurchase program Received FDA 510(k) clearance for next-generation AffloVest airway clearance device “We delivered a strong start to 2026, with first quarter revenue growth of 23% year-over-year driven by disciplined execution of our strategic priorities,” said Sheri Dodd, Chief Executive Officer of Tactile Medical.

20.04.2026

Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026

MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2026 financial results will be released after the market closes on Monday, May 4, 2026.

08.04.2026

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

23.03.2026

3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes

GMED, TCMD and IRMD tap GenAI to boost diagnostics and workflows, but high costs, regulation gaps and macro pressures still weigh on MedTech growth.

Videos

No Data

There is no data to display

Press releases

04.05.2026

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

09.03.2026

Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson

MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Andrea Pearson to the Company's Board of Directors (“Board”) and as a member of the Compliance & Reimbursement and Nominating & Corporate Governance Committees, effective March 9, 2026.

17.02.2026

Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

MINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Summary: Total revenue increased 21% year-over-year to $103.6 million Gross margin of 78% versus 75% in Q4 2024 Net income of $10.6 million versus $9.7 million in Q4 2024 Adjusted EBITDA of $22.9 million versus $16.2 million in Q4 2024 Full Year 2025 Summary: Total revenue increased 12% year-over-year to $329.5 million Gross margin of 76%, compared to 74% in 2024 Operating cashflow of $42.8 million, compared to $40.7 million in 2024 Repaid full outstanding principal balance of $26.3 million under the Company's term loan Repurchased $26.5 million of stock at an average price of $12.36 per share Ended 2025 with $83.4 million in cash, compared to $94.4 million at the end of 2024 Recent Business Highlights Acquired LymphaTech, expanding our lymphedema solutions portfolio and strengthening our R&D capabilities with their digital 3D scanning technology for chronic swelling detection, measurement, and monitoring Announced the publication of two-month clinical data comparing Flexitouch Plus™ to usual care in the Journal of the Sciences and Specialties of the Head and Neck “In 2025, we executed with discipline against our core growth strategies, delivering double-digit revenue growth, expanding gross margin and adjusted EBITDA, and generating strong cash flow, while continuing to strategically invest in people and workflow-related processes to strengthen our business for scale,” said Sheri Dodd, Chief Executive Officer of Tactile Medical.

17.02.2026

Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio

LymphaTech's 3D Platform and Digital Capabilities to Improve Disease Identification, Accelerate Therapy Adoption, and Support Next-Generation Lymphatic Therapies LymphaTech's 3D Platform and Digital Capabilities to Improve Disease Identification, Accelerate Therapy Adoption, and Support Next-Generation Lymphatic Therapies

Tactile Systems Technology, Inc. (TCMD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tactile Systems Technology, Inc. (TCMD)

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript

Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes

Videos

No Data

Press releases

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson

Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript

Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes

Videos

No Data

Press releases

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson

Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio

Search stocks

Tactile Systems Technology, Inc. (TCMD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Tactile Systems Technology, Inc. (TCMD)

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript

Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes

Videos

No Data

Press releases

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson

Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript

Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026

Should Value Investors Buy Tactile Systems Technology (TCMD) Stock?

3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes

Videos

No Data

Press releases

Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results

Tactile Medical Strengthens Board of Directors with Appointment of Andrea Pearson

Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

Tactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions Portfolio